Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MAP2K1 |
Variant | K57E |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | MAP2K1 K57E lies within the negative regulatory region of the Map2k1 protein (PMID: 24241536). K57E confers a gain of function to Map2k1 as demonstrated by increased activation of downstream Erk1/2 (PMID: 24463458, PMID: 25370473) and increased transformation in cultured cells and increased proliferation in a competition assay (PMID: 36442478), and is associated with Braf inhibitor resistance in cell culture (PMID: 24463458, PMID: 25370473, PMID: 36442478). |
Associated Drug Resistance | Y |
Category Variants Paths |
MAP2K1 mutant MAP2K1 act mut MAP2K1 K57E |
Transcript | NM_002755.4 |
gDNA | chr15:g.66435115A>G |
cDNA | c.169A>G |
Protein | p.K57E |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017022411.2 | chr15:g.66435115A>G | c.169A>G | p.K57E | RefSeq | GRCh38/hg38 |
NM_002755 | chr15:g.66435115A>G | c.169A>G | p.K57E | RefSeq | GRCh38/hg38 |
XM_017022411 | chr15:g.66435115A>G | c.169A>G | p.K57E | RefSeq | GRCh38/hg38 |
NM_002755.3 | chr15:g.66435115A>G | c.169A>G | p.K57E | RefSeq | GRCh38/hg38 |
NM_002755.4 | chr15:g.66435115A>G | c.169A>G | p.K57E | RefSeq | GRCh38/hg38 |
XM_017022411.3 | chr15:g.66435115A>G | c.169A>G | p.K57E | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 K57E | melanoma | resistant | Dabrafenib | Preclinical | Actionable | In a preclinical study, MAP2K1 (MEK1) K57E mutations restored extracellular signal-regulated kinase (ERK) activation in the presence of Tafinlar (dabrafenib) in cultured melanoma cell lines (PMID: 24463458). | 24463458 |
MAP2K1 K57E | Advanced Solid Tumor | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 K57E in culture (PMID: 36442478). | 36442478 |
MAP2K1 K57E | melanoma | sensitive | Binimetinib + Encorafenib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57E in culture (PMID: 36442478). | 36442478 |